The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com



Lisata Therapeutics Inc (CLBS)

Caladrius Biosciences is a clinical-stage biopharmaceutical company focused on the development of treatments and reversal of severe diseases. Co.'s product candidates include: XOWNA®, which is a Phase 2a study and an ongoing follow-on Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction; HONEDRA®, which is eligible for early conditional approval in Japan for the treatment of critical limb ischemia based on the results of a clinical trial; and CLBS201, which is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes.

Company Name:  Lisata Therapeutics Inc
Website:  www.caladrius.com
Sector:  Biotechnology
March 28, 2024    1:40 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree CLBS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Lisata Therapeutics Inc (CLBS) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.